Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Higher demand in the aircraft and energy-related markets, steady progress on orders already received, resilient performance in the industrial pumps and systems business and precision equipment business, increased shipments of parts for commercial aircraft, growth in overseas hemodialysis markets, the impact of the weaker yen and recognition of a ¥1,002 million foreign exchange gain, among other factors.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥118,415 million (YoY +18.0%) |
| Operating profit | ¥9,022 million (YoY +53.8%) |
| Ordinary income | ¥10,396 million (YoY +114.5%) |
| Profit attributable to owners of the parent | ¥8,257 million (YoY +67.5%) |
| Net income per share | ¥126.44 |
| Equity ratio | End of the current fiscal period 46 / End of previous period 44.2 |
| Total assets | ¥374,083 million |
| Net assets | ¥173,912 million |
| Cash flows from operating activities | ¥-2,088 million |
| Cash flows from investing activities | ¥-3,671 million |
| Cash flows from financing activities | ¥-1,465 million |
| Cash and cash equivalents at end of period | ¥37,983 million |
| Full-year earnings forecast | Net Sales ¥247,700 million (YoY +14.9%) / Operating profit ¥19,700 million (YoY +28.5%) / Income before taxes ¥20,000 million (YoY +15.9%) / Profit for the period attributable to owners of the parent ¥15,800 million (YoY +15.7%) |
| Annual Dividend Forecast | ¥40 → ¥60（+50.0%） |
| Segment revenue | Industrial business ¥78,088 million (YoY +26.3%), Medical business ¥40,346 million (YoY +4.6%) |
| Segment profit | Industrial business ¥7,317 million (YoY +63.8%), Medical business ¥3,524 million (YoY +35.9%) |
| Orders received and order backlog | Orders received ¥133,862 million / Order backlog Not disclosed |
| Depreciation and amortization | ¥5,802 million |
| Impairment loss | No impairment loss was recognized during the interim period (impairment loss or reversal: "-") |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (audience: Not disclosed) |
| Issued Shares at Period-End | 69,175,664 |
| Treasury Shares at Period-End | 3,822,482 |
| Factors Behind Changes in Business Performance | Higher demand in the aircraft and energy-related markets, steady progress on orders already received, resilient performance in the industrial pumps and systems business and precision equipment business, increased shipments of parts for commercial aircraft, growth in overseas hemodialysis markets, the impact of the weaker yen and recognition of a ¥1,002 million foreign exchange gain, among other factors. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and profit increased owing to higher demand in the aircraft and energy-related markets, steady progress on orders already received, increased shipments of aircraft parts and growth in overseas hemodialysis markets. Pretax interim profit and interim profit attributable to owners of the parent also benefited significantly from the recognition of a ¥1,002 million foreign exchange gain. The full-year forecasts were revised based on interim results exceeding the initial forecasts, as well as current business conditions and foreign exchange trends.